News
Media
Conferences
CME/CE
Partners
Publications
Resources
Subscribe

Opinion|Videos|October 31, 2024

Epilepsy in Pediatric Population: Prevalence, Pathophysiology, and Disease Heterogeneity

Author(s)John Michael Schreiber, MD

Key Takeaways

Pediatric epilepsy affects 0.5-1% of children, with increased prevalence in those with developmental disabilities.
Abnormal electrical brain activity, genetic mutations, structural abnormalities, and metabolic disorders contribute to epilepsy pathophysiology.
Diverse etiologies and seizure types in pediatric epilepsy complicate diagnosis, necessitating comprehensive evaluation and individualized treatment.

SHOW MORE

John Michael Schreiber, MD, provides an overview of epilepsy in infant and pediatric patients, including its prevalence, and describes the pathophysiology of infantile and pediatric epilepsy, highlighting how the disease’s heterogeneity affects diagnosis.

Episodes in this series

EP. 1 Epilepsy in Pediatric Population: Prevalence, Pathophysiology, and Disease Heterogeneity

EP. 1 Epilepsy in Pediatric Population: Prevalence, Pathophysiology, and Disease Heterogeneity

EP. 2 Types of Genetic Testing for Epilepsy Diagnosis

EP. 2 Types of Genetic Testing for Epilepsy Diagnosis

EP. 3 Key Considerations for Genetic Testing Selection in Pediatric Patients with Epilepsy

EP. 3 Key Considerations for Genetic Testing Selection in Pediatric Patients with Epilepsy

EP. 4 Importance of Genetic Testing for Pediatric Epilepsy Diagnosis and Treatment Decisions

EP. 4 Importance of Genetic Testing for Pediatric Epilepsy Diagnosis and Treatment Decisions

EP. 5 Importance of Genetic Counseling and Next-Generation Sequencing for Pediatric Epilepsy Diagnosis

EP. 5 Importance of Genetic Counseling and Next-Generation Sequencing for Pediatric Epilepsy Diagnosis

Please provide an overview of epilepsy in infant and pediatric patients.
- What is the prevalence of epilepsy in pediatric patients?
Please describe the pathophysiology of infantile and pediatric epilepsy.

How does the heterogeneity of the disease affect diagnosis?

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Latest CME

2026 Carolina Neuromuscular Disease Summit

In-Person + Virtual Event

2026 Carolina Neuromuscular Disease Summit

September 19-20, 2026

Increasing Awareness of Therapeutic Options for Thymidine Kinase 2 Deficiency (TK2d)

In-Person Event

Increasing Awareness of Therapeutic Options for Thymidine Kinase 2 Deficiency (TK2d)

October 16, 2026

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Zarazuela Zolkipli-Cunningham, MBChB, MRCP; Mary Kay Koenig, MD; Perry Shieh, MD, PhD, FAAN, FANA

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Karissa Gable, MD

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Anne M. Connolly, MD, FAAN; Amy Moore, PhD

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Jessica Oswald, MD, MPH; Jeremy A. Adler, DMSc, PA-C; Amanda Nasser, MS, NP

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA, FASCO; Girish Dhall, MD

Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis

Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis

Abigail Schwaede, MD; Alexis Lizarraga, MD, MS

Community Collab™: Identifying the Role of Complement Inhibitors in the Management of Generalized Myasthenia Gravis

Community Collab™: Identifying the Role of Complement Inhibitors in the Management of Generalized Myasthenia Gravis

James F. Howard Jr, MD, FAAN; Tuan Vu, MD

Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

James F. Howard Jr, MD, FAAN; Tuan Vu, MD

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

uniQure Submits BLA for Gene Therapy in HD, AAN, AHS Issue Updated Guideline on Migraine Prevention, CTE Prevalence, Brain Donation Findings in Former NFL Players

Phase 4 Study Highlights Valbenazine's Positive Impact on Patient-Reported Quality of Life, Daily Functioning in Tardive Dyskinesia

FDA Action Update, August 2026: Approvals, Clearances, and Designations

FDA Approves Zilganersen, First Treatment for Alexander Disease

Study Shows DMTs Associated With Higher Risk of Gynecologic Complications in Women With MS